NDAINTRAVENOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug Shortage Active
METHOTREXATE is currently in shortage. Reason: Manufacturing discontinuation. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
METHOTREXATE (methotrexate) by Accord Biopharma is reductase. Approved for rheumatoid arthritis, psoriatic arthritis, psoriasis and 4 more indications. First approved in 2020.
Drug data last refreshed 19h ago
Mechanism of Action
reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively…
Indications (7)
Worked on METHOTREXATE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.